Advice

Advice has been withdrawn from the website

fosaprepitant (Ivemend®) 115mg powder for solution for infusion for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy was reviewed by SMC in October 2008.  However from 15 February,2011, fosaprepitant (Ivemend®) 115mg powder for solution for infusion ceased to be available in the UK and therefore the SMC advice has been removed from the website.

Medicine details

Medicine name:
fosaprepitant (Ivemend)
SMC ID:
506/08
Indication:
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy
Pharmaceutical company
MSD
BNF chapter
Central nervous system
Submission type
Full submission
Status
Withdrawn
Date advice published:
13 October 2008